Yasmin, Yaz Blood Clot Risk Updated on Warning Label

New warnings are being added about the increased risk of blood clots from Yaz and Yasmin, as well as all birth control pills that use the progestin drospirenone. 

The FDA issued a drug safety communication on Tuesday, announcing the updated warning label following a review of a number of studies that suggest drospirenone birth control pills may more dangerous than other oral contraceptives containing levonorgestrel or some other progestins.

Drospirenone is a newer type of progestin that is used in combination with estrogen to prevent pregnancy.  It was first introduced in Yasmin birth control by Berlex Laboratories, which was later acquired by Bayer.  Yaz is an updated version of the birth control pill, and Bayer recently introduced a third variation, marketed as Beyaz, which also includes a folate supplement. There are also a number of generic and low-dose versions available.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The FDA indicates that there are still a number of factors that make drospirenone’s link to increased blood clot risk unclear. The studies do not provide the agency with consistent estimates of the comparative blood clot risks between pills with and without drospirenone, and they also do not account for some important patient characteristics that could affect blood clot risk.

The revised labels will state that some studies report that Yaz side effects may triple the risk of blood clots when compared to pills containing other progestins, but notes that some studies found no increased risk. The labels will include data from the FDA’s own study, which determined that drospirenone-based birth control pills were associated with a 1.5-fold increase in blood clot risk.

The new warnings are likely to factor into product liability lawsuits filed over the birth control pills, which allege that Bayer failed to adequately research the medication or provide clear warnings about the increased risk of blood clots compared to older birth control pills.

Over ten thousand women are currently pursuing a Yaz lawsuit, Yasmin lawsuit, Beyaz lawsuit or Ocella lawsuit against Bayer.

Earlier this year, the federal judge presiding over all lawsuits filed in U.S. District Courts throughout the United States ordered Bayer and plaintiffs’ lawyers to engage in Yaz settlement negotiations before the first cases are submitted to a jury.  Known as bellwethers, those early trial dates are often used to facilitate discussions to settle other lawsuits, and may help the parties gauge how juries are likely to respond to evidence that is likely to be introduced in multiple cases.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks
Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks (Posted yesterday)

Women who used Johnson's Baby Powder around their genitals for feminine hygiene purposes now live in fear of developing ovarian cancer, according to the class action lawsuit seeking medical monitoring for future diagnoses

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted 2 days ago)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.